P. Artru

J. Taieb, C. Coutzac, S. Pernot, 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients

A. de Gramont, B. Landi, T. André, 2006, British Journal of Cancer.

[Oral 5-FU and digestive cancers].

J. Taïeb, P. Artru, J. Desramé, 2004, Gastroenterologie clinique et biologique.

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly

J. Ezenfis, I. Etienney, T. Aparicio, 2003, British Journal of Cancer.

Predictors of disease-free survival in colorectal cancer with microsatellite instability: An AGEO multicentre study.

J. Taïeb, D. Vernerey, J. Pagès, 2015, European journal of cancer.

Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study

D. Vernerey, J. Taieb, R. Coriat, 2020, International journal of cancer.

Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer.

C. Tournigand, A. de Gramont, T. André, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant treatment of colon cancer: Xelox considered as commonplace therapy?

G. Lledo, P. Artru, 2012 .

Prognostic factors of Colorectal Cancer patients with Brain Metastases.

A. Lièvre, D. Tougeron, J. Bennouna, 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study.

L. Mineur, A. de Gramont, A. Gramont, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study

S. Truant, A. Lièvre, P. Devos, 2022, World Journal of Surgical Oncology.

BRAF V600E-Mutant Colorectal Cancers with Liver-Only Metastases: A Retrospective Study.

S. Truant, A. Lièvre, P. Devos, 2021 .

Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial.

F. Bidard, J. Pierga, O. Bouché, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Mifepristone for ectopic ACTH secretion in metastatic endocrine carcinomas: report of two cases.

C. Lombard-Bohas, J. Riou, P. Cassier, 2008, European journal of endocrinology.

Improvement of the CD4 cell count after alcohol withdrawal in HIV-positive alcoholic patients.

S. Pol, P. Berthelot, B. Nalpas, 1996, AIDS.

RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study

P. Laurent-Puig, H. Blons, O. Bouché, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wtKRAS metastatic colorectal cancer: A randomized phase II study (Prodige 18 –UNICANCER GI).

T. Conroy, G. Deplanque, C. Borg, 2016 .

[Primary hyperparathyroidism associated with colon cancer].

C. Tournigand, E. Lucchi, A. de Gramont, 2001, Gastroenterologie clinique et biologique.

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)

M. Moore, D. Goldstein, D. Vernerey, 2016, British Journal of Cancer.

Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm

M. Ychou, B. Dréno, M. Richard, 2012, Supportive Care in Cancer.

Factoring drug-free intervals into the management of patients with advanced colorectal cancer

C. Tournigand, A. Larsen, A. Gramont, 2007 .

Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study.

C. Tournigand, P. Laurent-Puig, F. Penault-Llorca, 2013 .

Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.

D. Goldstein, O. Bouché, F. Bonnetain, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

533PA large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability

J. Taieb, R. Coriat, T. André, 2017 .

FOLFIRI.3 (CPT-11 plus folinic acid plus 5-FU) alternating with gemcitabine or gemcitabine (G) alone in patients (pts) with previously untreated metastatic pancreatic adenocarcinoma (MPA): Results of the randomized multicenter AGEO phase II trial FIRGEM.

F. Fein, F. Bonnetain, J. Taieb, 2012 .

Outcomes of surgical management for borderline (BR)/locally advanced (LA) pancreatic adenocarcinoma (PAC) after neoadjuvant FOLFIRINOX chemotherapy: Results of an AGEO/French multicenter study.

J. Vaillant, J. Blanc, R. Coriat, 2014 .

A phase II study of gemcitabine and oxaliplatin (gemox) in advanced biliary adenocarcinoma (ABA). Preliminary results

C. Tournigand, F. Selle, A. Gramont, 2001 .

D. Goldstein, O. Bouché, F. Bonnetain, 2013, Journal of Clinical Oncology.

Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study.

M. Boubaya, V. Boige, R. Coriat, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Computed tomography scan efficacy in staging gastric linitis plastica lesion: a retrospective multicentric French study

R. Coriat, T. Walter, C. Brézault, 2018, Cancer management and research.

Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA Cohort

I. Ray-Coquard, D. Tavan, Floriane Huet-Penz, 2022, Cancers.

Efficacy of EUS-guided hepaticogastrostomy in prolonging survival of patients with perihilar cholangiocarcinoma

B. Napoléon, S. Leblanc, F. Fumex, 2022, Endoscopic ultrasound.

Gemcitabine, oxaliplatin (GEMOX) and cetuximab for treatment of hepatocellular carcinoma (HCC): Results of the phase II study ERGO

M. Hebbar, J. Taieb, T. Poynard, 2007 .

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.

M. Ychou, E. Assenat, J. Biagi, 2022, JAMA oncology.

FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study.

J. Taïeb, J. Spano, J. Taieb, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Lecomte, Sophie Gourgou, T. Conroy, 2018, The New England journal of medicine.

Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective

E. Assenat, J. Sabourin, R. Coriat, 2023, Targeted Oncology.

[Gastrin-17 and G17-gly induce proliferation of LoVo cells through the CCK B/gastrin receptor].

A. Bado, S. Attoub, P. Artru, 1998, Gastroenterologie clinique et biologique.

Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.

E. Touboul, R. Labianca, P. Ruszniewski, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

C. Tournigand, P. Laurent-Puig, F. Penault-Llorca, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study

A. Lièvre, J. Taieb, D. Tougeron, 2022, British Journal of Cancer.

T. Conroy, C. Borg, O. Bouché, 2021, Clinical colorectal cancer.

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial

T. Conroy, C. Borel, G. Deplanque, 2019, JAMA oncology.

Characteristics of BRAF V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients.

A. Lièvre, W. Cacheux, R. Guimbaud, 2019, The oncologist.

MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer.

N. Rioux-Leclercq, F. Beuvon, A. Lièvre, 2022, Clinics and research in hepatology and gastroenterology.

Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.

J. Taieb, D. Tougeron, S. Pernot, 2020, Clinics and research in hepatology and gastroenterology.

Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study

D. Pezet, J. Taieb, D. Tougeron, 2019, Therapeutic advances in gastroenterology.

How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort

J. Vaillant, A. Sauvanet, O. Hentic, 2018, Annals of Surgical Oncology.

A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort

S. Truant, M. Ychou, P. Colombo, 2018, BMC Cancer.

Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study.

A. Lièvre, M. Pracht, J. Edeline, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial

F. Fein, F. Bonnetain, J. Taieb, 2015, PloS one.

FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

J. Taieb, T. Aparicio, M. Gauthier, 2014, BMC Cancer.

Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study.

C. Tournigand, F. Bonnetain, A. Larsen, 2011, The oncologist.

Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment

M. Ychou, E. Assenat, C. Borg, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).

J. Taïeb, F. Fein, F. Bonnetain, 2014, European journal of cancer.

Tumor budding is an independent prognostic factor in stage III colon cancer patients: A post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).

J. Emile, F. Ghiringhelli, D. Vernerey, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology

F. Fein, F. Bonnetain, J. Taieb, 2016, Quality of Life Research.

[Definitive treatment of anal canal carcinoma with radiotherapy: adverse impact of a pre-radiation resection. A retrospective study of 57 patients treated with curative intent].

G. Lledo, P. Artru, S. Taieb, 2009, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer.

C. Tournigand, J. Taïeb, A. de Gramont, 2002, European journal of cancer.

Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma

M. Hebbar, J. Taieb, T. Poynard, 2008, Cancer.

Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High‐Risk Stage III (pT4 and/or N2) Colon Cancer—A UNICANCER GI‐PRODIGE Trial

S. Gill, J. Emile, J. Taïeb, 2019, Clinical colorectal cancer.

Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.

C. Tournigand, L. Mineur, A. Larsen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 - REGOLD.

C. Lepage, A. Dohan, N. Baize, 2020, Journal of geriatric oncology.

Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastric or gastroesophageal junction carcinoma.

M. Ducreux, P. Rougier, J. Taïeb, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of pneumatic dilatation in patients with dysphagia after antireflux surgery

S. Chaussade, D. Couturier, M. Gaudric, 1999, The British journal of surgery.

Management of Patients with Pancreatic Ductal Adenocarcinoma in the Real-Life Setting: Lessons from the French National Hospital Database

I. Ray-Coquard, V. Hervieu, M. Adham, 2021, Cancers.

Evaluation of two nutritional scores' association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre study.

A. Lièvre, J. Taieb, S. Pernot, 2019, European journal of cancer.

Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma.

M. Ducreux, P. Rougier, J. Taïeb, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of short course radiotherapy with chemoradiotherapy for locally advanced rectal cancers in the elderly: A multicentre, randomised, non-blinded, phase 3 trial.

N. Magné, V. Boige, B. De Bari, 2022, European journal of cancer.

Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma

C. Tournigand, A. de Gramont, C. Louvet, 2001, Cancer.

1204MO PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma

K. Le Malicot, C. Louvet, D. Tougeron, 2022, Annals of Oncology.

Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma—a retrospective, international, multicentric AGEO study

G. Prager, R. Guimbaud, L. Mineur, 2023, Gastric Cancer.

LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)

M. Ychou, E. Assenat, O. Bouché, 2021, Annals of Oncology.

Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer

J. Douillard, H. Naman, P. Piedbois, 2007, British Journal of Cancer.

Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).

C. Tournigand, J. Lotz, A. de Gramont, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study

A. Lièvre, P. Hammel, J. Taieb, 2022, International journal of cancer.

Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study

O. Bouché, F. Bonnetain, J. Taieb, 2017, Oncotarget.

Quel dépistage pour le cancer colorectal en l'an 2003 ?

P. Artru, 2003 .

Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study

J. Taieb, D. Tougeron, P. Artru, 2018, Targeted Oncology.

High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).

J. Lotz, A. de Gramont, A. Gramont, 2001, European journal of cancer.

FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study.

C. Tournigand, M. Buyse, A. Figer, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemoradiation with FOLFOX plus cetuximab in locally advanced cardia or esophageal cancer: Final results of a GERCOR phase II trial (ERaFOX).

L. Mineur, F. Di Fioré, A. de Gramont, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.

C. Tournigand, B. Gayet, J. Taïeb, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study

P. Laurent-Puig, H. Blons, O. Bouché, 2019, Cancers.

Digital tool to identify and monitor regorafenib-associated hand-foot skin reactions: A proof-of-concept study protocol

V. Bourgeois, M. Palma, R. Coriat, 2023, Digestive and Liver Disease.

RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.

A. Lièvre, P. Laurent-Puig, M. Ducreux, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

RAS mutations concordance in circulating tumor DNA (ctDNA) and tissue in metastatic colorectal cancer (mCRC): RASANC, an AGEO prospective multicenter study.

P. Laurent-Puig, H. Blons, O. Bouché, 2017 .

Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial.

J. Taieb, O. Pellerin, E. Watkin, 2015, Clinics and research in hepatology and gastroenterology.

Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study

C. Lepage, R. Guimbaud, J. Raoul, 2020, British Journal of Cancer.

Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study

C. Lepage, R. Guimbaud, J. Raoul, 2020, British Journal of Cancer.

Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX.

F. Bonnetain, L. Mineur, F. Di Fioré, 2016, European journal of cancer.

Improving safety in first-line metastatic colorectal cancer (MCRC) therapy with bevacizumab: Modified FOLFOX7 versus XELOX2—Results of the induction phase of the GERCOR DREAM randomized phase III study.

C. Tournigand, W. Scheithauer, F. Bonnetain, 2015 .